Krystal Biotech, Inc. (KRYS)
- Previous Close
157.68 - Open
158.03 - Bid 158.18 x 100
- Ask 159.00 x 100
- Day's Range
155.95 - 160.07 - 52 Week Range
86.03 - 189.97 - Volume
197,304 - Avg. Volume
395,379 - Market Cap (intraday)
4.533B - Beta (5Y Monthly) 0.90
- PE Ratio (TTM)
73.15 - EPS (TTM)
2.17 - Earnings Date Aug 5, 2024 - Aug 9, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
189.00
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
www.krystalbio.comRecent News: KRYS
Performance Overview: KRYS
Trailing total returns as of 5/9/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KRYS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KRYS
Valuation Measures
Market Cap
4.53B
Enterprise Value
4.00B
Trailing P/E
72.81
Forward P/E
178.57
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
47.39
Price/Book (mrq)
5.67
Enterprise Value/Revenue
41.72
Enterprise Value/EBITDA
66.34
Financial Highlights
Profitability and Income Statement
Profit Margin
59.57%
Return on Assets (ttm)
-4.97%
Return on Equity (ttm)
8.87%
Revenue (ttm)
95.95M
Net Income Avi to Common (ttm)
57.16M
Diluted EPS (ttm)
2.17
Balance Sheet and Cash Flow
Total Cash (mrq)
538.26M
Total Debt/Equity (mrq)
0.99%
Levered Free Cash Flow (ttm)
-45.19M
Research Analysis: KRYS
Company Insights: KRYS
KRYS does not have Company Insights